Keytruda/Inlyta Data Stoke Competition In Kidney Cancer

 
• By John Davis

Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.

Racing
Competition between first-line combinations for advanced RCC is intense • Source: Shutterstock

More from Immuno-oncology

More from Anticancer